Literature DB >> 1939523

Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men.

A Iranmanesh1, G Lizarralde, J D Veldhuis.   

Abstract

Mean plasma GH concentrations are controlled by the frequency, amplitude, and duration of underlying GH secretory bursts as well as by the half-life of endogenous GH. We investigated the specific mechanisms that subserve the clinically recognized negative effects of age and adiposity on mean serum GH concentrations. To this end, 21 healthy men, aged 21-71 yr, who were of nearly normal body weight underwent blood sampling at 10-min intervals for 24 h. Deconvolution analysis was used to estimate specific features of GH secretion and clearance. Compared to younger men, the older tertile of men had significant reductions in 1) GH secretory burst frequency, 2) the half-life of endogenous GH, and 3) the daily GH secretory rate, but not 4) GH secretory burst half-duration, amplitude, or mass. Linear regression analysis disclosed that age was a major negative statistical determinant of GH secretory burst frequency (r = -0.80; P = 0.005) and endogenous GH half-life (r = -0.70; P = 0.024). Body mass index, an indicator of relative obesity, was a significant negative correlate of GH half-life (P = 0.045) and GH secretory burst amplitude (P = 0.031). Age and body mass index each correlated negatively with the daily GH secretion rate (P = 0.0031 and P = 0.027, respectively), and together accounted for more than 60% of the variability in 24-h GH production rates (r = -0.78; P = 0.00056). On the average, for a normal body mass index, each decade of increasing age attenuated the GH production rate by 14% and the GH half-life by 6%. Conversely, each unit increase in body mass index, at a given age, reduced the daily GH secretion rate by 6%. We conclude that age and relative adiposity are distinct and specific correlates of individual attributes of GH secretion and clearance in men.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939523     DOI: 10.1210/jcem-73-5-1081

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  116 in total

1.  Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors.

Authors:  A Colao; G Cerbone; R Pivonello; M Klain; G Aimaretti; A Faggiano; C Di Somma; M Salvatore; G Lombardi
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 2.  Neuroendocrine control of GH release during acute aerobic exercise.

Authors:  A Weltman; L Wideman; J Y Weltman; J D Veldhuis
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 4.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

5.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

6.  Pituitary physiological and ultrastructural changes during aging.

Authors:  A C Nessi; G De Hoz; C Tanoira; E Guaraglia; G Consens
Journal:  Endocrine       Date:  1995-10       Impact factor: 3.633

Review 7.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 8.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

Review 9.  Muscle wasting and cachexia in heart failure: mechanisms and therapies.

Authors:  Stephan von Haehling; Nicole Ebner; Marcelo R Dos Santos; Jochen Springer; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2017-04-24       Impact factor: 32.419

10.  Testosterone and growth hormone improve body composition and muscle performance in older men.

Authors:  Fred R Sattler; Carmen Castaneda-Sceppa; Ellen F Binder; E Todd Schroeder; Ying Wang; Shalender Bhasin; Miwa Kawakubo; Yolanda Stewart; Kevin E Yarasheski; Jagadish Ulloor; Patrick Colletti; Ronenn Roubenoff; Stanley P Azen
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.